Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Q Hu, Y **ong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations
Starting from our previous finding of 14 known drugs as inhibitors of the main protease
(Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak …
(Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
and the associated disease COVID-19, requires therapeutic interventions that can be rapidly …
and the associated disease COVID-19, requires therapeutic interventions that can be rapidly …
Targeting the main protease of SARS‐CoV‐2: from the establishment of high throughput screening to the design of tailored inhibitors
J Breidenbach, C Lemke, T Pillaiyar… - Angewandte Chemie …, 2021 - Wiley Online Library
The main protease of SARS‐CoV‐2 (Mpro), the causative agent of COVID‐19, constitutes a
significant drug target. A new fluorogenic substrate was kinetically compared to an internally …
significant drug target. A new fluorogenic substrate was kinetically compared to an internally …
Transformer-based molecular generative model for antiviral drug design
Since the Simplified Molecular Input Line Entry System (SMILES) is oriented to the atomic-
level representation of molecules and is not friendly in terms of human readability and …
level representation of molecules and is not friendly in terms of human readability and …
Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase
F Munafò, E Donati, N Brindani, G Ottonello… - Scientific Reports, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a
global health pandemic. Among the viral proteins, RNA-dependent RNA polymerase (RdRp) …
global health pandemic. Among the viral proteins, RNA-dependent RNA polymerase (RdRp) …
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …
essential for viral replication.•The effective target for drug development has been the M …